EUDA
EUDA Health Holdings Limited2.4000
+0.1400+6.19%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
90.74MP/E (TTM)
120.00Basic EPS (TTM)
0.02Dividend Yield
0%Recent Filings
10-Q
Q1 FY2023 results
EUDA Health Holdings swung to a net loss of $2.4M for Q1 2023 ended March 31, down sharply from $0.2M profit a year earlier, as revenues fell 36.3% y/y to $1.7M amid softer medical services demand and fewer property units managed. Gross profit plunged 68.3% y/y to $0.4M, with margins contracting to 23.8% from 47.7% due to higher third-party clinic costs; operating loss hit $2.0M versus $0.1M income, driven by $1.2M y/y spike in G&A from professional fees. Cash edged up to $0.8M, bolstered by $0.5M in related-party financing, while total debt stood at $3.9M including convertibles; free cash flow not disclosed in the 10-Q. Yet liquidity strains persist with a $6.5M working capital deficit. Intense competition erodes client base.
10-K
FY2022 results
EUDA Health Holdings swung to a $24.9 million net loss in FY2022, driven by a $12.9 million hit from fair value changes in prepaid forward purchase liabilities and $5.2 million in earnout shares, despite revenues dipping 6.7% to $9.8 million amid a 17.4% drop in property management to $3.8 million—yet medical services grew 5.9% to $6.1 million on higher corporate client usage. Q4 momentum faltered with no quarterly breakdowns disclosed, but annual gross margins compressed to 34.1% from 40.3% as medical costs rose 25.1% without related-party discounts. Cash burned $1.5 million in operations, leaving $0.8 million on hand against $4.1 million working deficit; no dividends or buybacks, capex minimal at $18,000. No 2023 guidance issued. Nasdaq delisting risk looms if filings lag.
8-K
Nasdaq compliance regained
EUDA Health Holdings resolved a Nasdaq compliance issue on June 13, 2023, by having CEO Dr. Kelvin Chen forfeit 271,867 shares from a prior settlement, adjusting the issuance price to $1.47 per share and satisfying Listing Rule 5635(c). Nasdaq also accepted the company's plan to file its delinquent 10-K and 10-Q by August 4, 2023, averting immediate delisting. Compliance restored. Yet failure to meet the deadline risks delisting and an appeal process.
8-K
EUDA settles CEO debt, accelerates forwards
EUDA Health Holdings amended its settlement with CEO Dr. Kelvin Chen on June 6, 2023, issuing 578,439 ordinary shares at $1.47 each to settle $850,306 in unpaid loans, while he forfeits 271,867 shares to meet Nasdaq rules. The company also accelerated prepaid forward agreements with two institutional sellers on June 8, issuing 1,600,000 ordinary shares as maturity consideration and allowing them to retain prior prepayments and shares. Board changes elevated Alfred Lim to Executive Director, effective immediately, reshaping committees. This settles obligations but dilutes equity.
8-K
Debt settled via equity issuance
EUDA Health Holdings settled outstanding debts totaling over $2 million with insiders by issuing 2,317,606 restricted ordinary shares on May 16, 2023, converting a $700,000 note at $1.00 per share while settling loans from CEO Kelvin Chen and others via equity. This cleared legacy obligations from 2022-2023, freeing up cash for operations. The company also raised $940,000 through a private placement of 940,000 shares at $1.00 to eight accredited investors between May 16-22. One small loan remains outstanding.
BALDF
FASTIGHETS AB BALDER
6.76+0.00
CSUI
Cannabis Suisse Corp.
0.00-0.00
FCHS
First Choice Healthcare Solutio
0.01+0.00
GYRO
Gyrodyne , LLC
9.17+0.00
LHAI
Linkhome Holdings Inc.
12.80-0.09
LRHC
La Rosa Holdings Corp.
0.79-0.08
MAYS
J. W. Mays, Inc.
38.25+0.00
OMH
Ohmyhome Limited
0.89-0.12
UHT
Universal Health Realty Income
41.76-0.46
UK
Ucommune International Ltd
0.87-0.03